Drug Therapy - Ophthalmology

POAG: Enigmatic group of heterogenous diseases?Various subtypes of primary open-angle glaucoma might exist. Continued research is needed to identify the characteristics of each subtype for better management.
Sustained-release insert aids patient noncomplianceThe current convention for treating pain and inflammation in postsurgical cataract patients is confusing, inconvenient, and expensive. Patient compliance with a self-administereddrop regimen is poor. Multiple studies confirm that the vast majority of patients fail to instill the drops properly or administer the drops as prescribed.
Promising advances in uveal melanoma treatmentImmunotherapy and other investigational treatments appear to be promising for uveal melanoma, according to Carol Shields, MD.
Non-invasive punctal plug delivery system offers a host of positive performance characteristics
Non-invasive punctal plug delivery system offers a host of positive performance characteristicsA silicone punctal plug-based delivery system for ophthalmic medications (Evolute, Mati Therapeutics) provides precisely controlled medication release into the tear film and has been associated with positive results in initial clinical testing.
The utility of normal tear osmolarity results
The utility of normal tear osmolarity resultsPatient symptoms are not an effective method to diagnose dry eye, as they often overlap with other pathologies. Tear osmolarity results provide clues for alternative diagnoses.
Lifitegrast data support dry eye efficacy over placebo dropsLifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
Bimatoprost insert offers noninvasive platform for early glaucoma patients A 19-month, open-label study of a novel bimatoprost, sustained-release ocular insert shows good safety and efficacy. The insert is polymer ring that sits atop the eye in the conjunctival fornix. Phase III trials are expected to begin in 2017.
Tracking infection source after blepharoplasty
Tracking infection source after blepharoplastyInfections after blepharoplasty are uncommon with or without the use of an antibiotic ointment. However, if infections occur, be suspicious of community-acquired methicillin-resistant Staphylococcus aureus (MRSA), said Mark A. Alford, MD.
Data support adding suprachoroidal injection to anti-VEGF for RVOResults from the phase II TANZANITE clinical trial support further investigation of adding suprachoroidal triamcinolone acetonide to anti-vascular endothelial growth factor therapy for treatment-naïve retinal vein occlusion.
Neuroprotective drug may be possible NAION therapyNon-arteritic ischemic optic neuropathy can be difficult to treat. A new drug under investigation aims to prevent further loss of vision from the condition.